Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 29, 2006

Filing Date
Filed February 27, 2007
Period End
December 29, 2006
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 27, 2007. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported a net loss of $101.5 milliona for the year ended December 2006, compared with $84.4 million in 2005 and $137.2 million in 2004.

Total revenues rose to $98.7 millionb from $76.0 million, with contract revenues of $62.4 million and license revenues of $36.3 million. Research and development expenses increased to $185.5 million, up from $141.1 million, and general and administrative expenses rose to $39.1 million. The accumulated deficit reached $705.3 million, and stockholders' equity was $52.5 million at year-end.

Liquidity is the central investor issue. The company held $263.2 millionc in cash, marketable securities, investments held by Symphony Evolution, Inc. (SEI), and restricted cash and investments at December 31, 2006, and states it expects these resources to fund operations for at least 12 months. The filing warns that future capital needs could require the company to use capital sooner than expected.

Its GlaxoSmithKline loan of $95.2 milliond carries financial covenants requiring working capital of at least $25.0 million and cash and investments of at least $50.0 million. Repurchasing the three SEI-licensed compounds (XL647, XL999 and XL784) could be required if GlaxoSmithKline selects one of them, and the filing notes the purchase price is tied to $80.0 million of invested capital plus 25% per year. Clinical and partnering developments dominate the outlook.

Enrollment in the XL999 Phase II program was suspended in November 2006 over cardiovascular adverse events, and the FDA placed the program on partial clinical hold in December 2006. In January 2007, Bristol-Myers Squibb made a $60.0 million upfront payment under a new collaboration, and Genentech's co-development of XL518 included $25.0 million paid in December 2006 and $15.0 million paid in January 2007. The company had 651 full-time employees at year-end 2006.

Key Highlights

  1. Net loss widened to $101.5 million in 2006 from $84.4 million in 2005, while total revenues increased to $98.7 million from $76.0 million.
  2. Research and development expenses rose to $185.5 million from $141.1 million, with the filing citing higher clinical trial activity and $11.2 million of stock-based compensation under SFAS 123R.
  3. Cash, marketable securities, SEI investments and restricted cash totaled $263.2 million at December 31, 2006, which the company says supports operations for at least 12 months.
  4. The XL999 program is on partial clinical hold following suspended enrollment in November 2006 due to increased serious cardiovascular events.
  5. Bristol-Myers Squibb paid a $60.0 million upfront fee in January 2007 under a new collaboration to select up to three IND candidates from six future compounds.
  6. The GlaxoSmithKline loan of $95.2 million carries working capital and cash-and-investments covenants of $25.0 million and $50.0 million, respectively.
  7. Accumulated deficit reached $705.3 million, and stockholders' equity was $52.5 million at December 31, 2006.

Frequently Asked Questions

  1. Can Exelixis fund its operations without raising more capital?

    The company states that its cash, marketable securities, SEI investments and expected collaborator funding should sustain operations for at least 12 months after December 31, 2006, assuming a moderate level of business development activity. It also warns that factors such as GlaxoSmithKline compound selections, SEI repurchase obligations and clinical results could require it to use capital sooner, and it may need to raise additional funds on unfavorable terms.

  2. What is the financial exposure related to Symphony Evolution, Inc.?

    SEI received $80.0 million from investors to fund clinical development of XL784, XL647 and XL999, and Exelixis holds an exclusive option to reacquire these compounds at a price equal to invested capital plus 25% per year. If GlaxoSmithKline selects any of these compounds for further development, Exelixis would have to repurchase all three, and it notes that GlaxoSmithKline milestones may cover only a small portion of that price.

  3. What happened with the XL999 program?

    Enrollment of new patients was suspended in November 2006 after an increase in serious cardiovascular events was observed. The FDA placed the program on partial clinical hold on December 1, 2006, allowing only enrolled patients to continue receiving XL999. The company does not know when or if enrollment will resume.

  4. What are the main sources of revenue?

    Revenues come from collaboration agreements with partners including GlaxoSmithKline, Bristol-Myers Squibb, Sankyo and Wyeth, which accounted for 28%, 22%, 15% and 14% of 2006 revenues, respectively. Revenue includes research and development funding of $46.3 million, milestones of $15.6 million, and amortization of upfront payments of $36.3 million.

  5. Does the company have any approved products?

    No. The filing states that Exelixis has not received regulatory approval to market any of its product candidates and has not generated revenues from the sale of pharmaceutical products. Its revenues to date come from license revenues, contract revenues and transgenic mouse services through its German subsidiary, Artemis.